A listing of human tumor antigens recognized by T cells.
about
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytesRecognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytesT-cell clonotypes in cancerClinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cellsHLA class I and II genotype of the NCI-60 cell linesCD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Immunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaConformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificityIncreased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking modeTumour immunology, vaccination and escape strategiesCancer/testis antigens: an expanding family of targets for cancer immunotherapyPrognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray studyIdentification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarrayMolecular mimics of the tumour antigen MUC1A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesSeroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.Proteomics in cancer vaccine development.A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaAntigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeuticsGlioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaProgress on new vaccine strategies for the immunotherapy and prevention of cancer.Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopesImmunotherapy of melanoma.Advances in the non-surgical treatment of melanoma.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.All in the head: obstacles for immune rejection of brain tumours.Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
P2860
Q24531276-E86AE56D-9DC9-4585-B337-B8B923B204ECQ24649346-A0DC73F4-8B88-4489-ACC2-DB431E1B5F5FQ24672952-0BD3F444-F687-4B44-AE26-9E8289B75803Q24803891-A308AEFE-4C05-4583-9740-A91DD0B7A3E5Q24804892-9A97C2C6-BEEA-47C4-BC4B-28E689E98127Q24805062-F1722035-255C-4BC1-977D-4B2ABCD0D733Q24815777-A90970E4-1350-4230-BB53-6DE20137EC3CQ25257888-5481593D-B4DE-4805-B502-DD5E3C15270EQ26866513-F2953236-F223-4450-BE55-6645946E6816Q27024830-C614AF90-8C3B-48C4-9102-9A76F7E83F95Q27653583-52237317-4710-4C32-B3C2-624B7CDDB8AFQ27678823-4DCC4CFE-7803-4EC5-AFEB-8ECE5358E008Q28208633-749CF9A8-C602-4206-A638-A83DAD8B2197Q28215652-2C9ECAD3-BE97-4A6E-AECD-AD0A480FF9C1Q28220500-F6C77FA7-A330-44F7-9DB6-AB2CEB5C964EQ28235811-6D75085A-FC5C-4063-A843-5EE58D8192A9Q28485169-D6F39AC5-2BF0-4D79-A12A-8D657BCC0D02Q30411499-71699CE8-B92D-42DD-95EE-BE7B3D970DBEQ30433911-02ECE672-AFC2-4595-967F-3B6B17B6AFC5Q30785776-3028A1F3-155D-4CAA-B807-999B92A21771Q33210267-306B65FC-2EDE-44EF-9932-7299D737DDE1Q33215044-56D36315-4AB0-485E-B8B4-8F1BAAF3BD7DQ33342339-145D5BCC-C55A-4B0E-B756-1B84B7C4E906Q33648189-DDE5361C-8214-4347-92D1-B887E9B0B3E3Q33999299-6F5CFAA1-2824-4302-A2BB-4B3BFBCC0796Q34035564-ABF87AFD-5E3B-42BC-AF9C-D622ADDAD9D0Q34198563-537A22EA-2AC7-4AFF-B5CF-A6FB6859D86DQ34328457-3DFC6256-6002-4930-B555-71AE7EE887D2Q34373182-E2271E58-9EB2-4C28-9A0E-AFC1472FB705Q34383950-7D490FAF-1D01-45A1-94ED-68FC6EFB00A1Q34481976-D70D0491-5114-4161-9EAF-0F1761EDDD0EQ34520155-72FCE77A-E895-4AC2-AEFF-955EE9EB335AQ34557233-B792E92E-319D-4261-97B2-4CD9A3DC1649Q34669820-EED68F18-5FD9-4B80-B7D3-82CAEA8AF42AQ34834369-24C04F08-7EDF-4FD5-978D-4E83485513C5Q34842204-A0356584-E9B8-486B-ADB6-4F3033C97190Q34994511-B3BD4ACA-66E1-4435-946A-2030CA6B1263Q35005935-A70E95BF-D152-4238-AC3A-1249BD8D908CQ35005940-227C8483-337A-4EE3-A76D-95D7E2F46DD2Q35005955-147C468C-9351-401D-9508-38C8BCC90D40
P2860
A listing of human tumor antigens recognized by T cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A listing of human tumor antigens recognized by T cells.
@ast
A listing of human tumor antigens recognized by T cells.
@en
type
label
A listing of human tumor antigens recognized by T cells.
@ast
A listing of human tumor antigens recognized by T cells.
@en
prefLabel
A listing of human tumor antigens recognized by T cells.
@ast
A listing of human tumor antigens recognized by T cells.
@en
P2093
P356
P1476
A listing of human tumor antigens recognized by T cells.
@en
P2093
Castelli C
Parmiani G
Renkvist N
Robbins PF
P2888
P356
10.1007/S002620000169
P577
2001-03-01T00:00:00Z
P5875
P6179
1051489272